Drug intelligence / Profile preview

MB-COL-1

Development stage: Preclinical
Lead developer: Mercury Bio
Modality: Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

MB-COL-1 is an intracellular immunotherapeutic nanobody developed by Mercury Holdings (Mercury Bio) for collagen regeneration. It is designed to be delivered into cells using the company's proprietary platform to interact with collagen or collagen-associated targets, aiming to promote tissue repair and regeneration. The candidate is currently in preclinical development.

Beyond the preview

Go deeper on MB-COL-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MB-COL-1.

Explore the full profile